CMMB (Chemomab Therapeutics) Research & Development: $4.27 Mil (TTM As of Mar. 2026)


CMMB Chemomab Therapeutics Ltd CMMB
33 GF Score
Price $1.59
View Full Analysis

What is Chemomab Therapeutics Research & Development?

Chemomab Therapeutics CMMB 33 Research & Development is $4.27 Mil as of Mar. 2026. GuruFocus rates CMMB with a GF Score™ of 33/100.

Research & Development is the aggregate amount of research and development expenses during the year. Chemomab Therapeutics's Research & Development for the three months ended in Mar. 2026 was $0.93 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $4.27 Mil.

Chemomab Therapeutics  (NAS:CMMB) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Chemomab Therapeutics Research & Development Related Terms

Chemomab Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Chemomab Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chemomab Therapeutics Research & Development Chart

Chemomab Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 6.33 16.98 18.38 11.33 5.83

Chemomab Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.49 1.29 0.96 1.09 0.93
CMMB
33GF Score
Chemomab Therapeutics Ltd CMMB
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chemomab Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.27 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $4.27 Mil mean?
Chemomab Therapeutics (CMMB) has a Research & Development of $4.27 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Chemomab Therapeutics and its competitors.
Is Chemomab Therapeutics' Research & Development too high?
Chemomab Therapeutics' current Research & Development is $4.27 Mil. Overall, Chemomab Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Chemomab Therapeutics' Research & Development compare to HCWB and MTVA?
Chemomab Therapeutics' Research & Development of $4.27 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Chemomab Therapeutics and its competitors. Chemomab Therapeutics's current Research & Development is $4.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemomab Therapeutics stock overvalued right now?
Chemomab Therapeutics (CMMB) has a current Research & Development of $4.27 Mil. The current Research & Development is $4.27 Mil. Chemomab Therapeutics' overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Chemomab Therapeutics (CMMB), the current Research & Development is $4.27 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Chemomab Therapeutics Business Description

Address 10 Habarzel Street, 10th Floor, Building C, Tel Aviv, ISR, 6158101
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.
33GF Score

Get the complete analysis for CMMB

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.59
Price